Alamar Biosciences (ALMR) analyst forecast and price target
Analyst forecast
Consensus of 5 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Overweight | $35.00 from $32.00 | Aug 11, 2026 |
| Stifel | Maintained | Buy | $32.00 from $28.00 | Aug 11, 2026 |
| Stifel | Initiated Coverage | Buy | $28.00 | May 12, 2026 |
| TD Cowen | Initiated Coverage | Buy | $30.00 | May 12, 2026 |
| JP Morgan | Initiated Coverage | Overweight | $30.00 | May 12, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $35.00 | May 12, 2026 |
Frequently asked questions
Is ALMR a buy, sell, or hold?
Analysts covering Alamar Biosciences currently average a Buy rating: 4 buy, 1 hold and 0 sell, from 5 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on ALMR?
On Aug 11, 2026, JP Morgan maintained Alamar Biosciences at Overweight with a price target of $35.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.